Search clinical trials for: BIIB 722 CL

Total 1102 results

Boehringer Ingelheim

Terminated

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

Healthy
Boehringer Ingelheim

Completed

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

Stroke
Boehringer Ingelheim

Completed

Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL

Healthy
Leiden University Medical Center
Takeda; Netherlands Brain Foundation

Recruiting

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury (CIAO@TBI)

Traumatic Brain Injury | Trauma, Head

Netherlands
HeNan Sincere Biotech Co., Ltd

Completed

A Study of CL-197 Capsules in Healthy Participants

HIV-1

China
Boehringer Ingelheim

Terminated

A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Seikagaku Corporation

Completed

PK and Safety of SI-722 in IC/BPS

Interstitial Cystitis | Bladder Pain Syndrome

United States
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Contour Research

Completed

Examination of Circumferential Reduction

Overweight or Obesity

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Terminated

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

Healthy
Boehringer Ingelheim

Completed

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
HeartWorks, Inc.

Recruiting

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Congenital Heart Disease | Univentricular Heart | Heart Failure NYHA Class III | Heart Failure NYHA Class IV

United States
University of Vermont

Completed

Role of Magnesium Supplementation in the Treatment of Depression

Depression

United States
Medecins Sans Frontieres, Netherlands

Terminated

Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan (HECT-CL)

Cutaneous Leishmaniases

Pakistan
LG Chem

Active, not recruiting

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

Healthy

United States
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Hepatic Insufficiency
Federico II University

Withdrawn

Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth

Preterm Birth

Italy
Boehringer Ingelheim

Completed

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Asthma
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects

Healthy
Boehringer Ingelheim

Terminated

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Cystic Fibrosis

United States
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Healthy

Germany
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Chinese University of Hong Kong

Not yet recruiting

The Influence of GNiib® in Obesity Management in Obese Young Individuals in Hong Kong.

Obesity
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Medtronic Diabetes

Completed

SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c (SWITCH)

Diabetes Mellitus, Type 1

Netherlands, Slovenia, Denmark, Austria, Italy, Luxembourg, Spain
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity

Spinal Cord Injuries
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

Healthy
Naval Medical Research Center

Unknown

Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru

Leishmaniasis, Cutaneous

Peru
Limacorporate S.p.a

Recruiting

H-35 CL TRAUMA Cemented Femoral Stem

Arthroplasty | Hip | Replacement

Italy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

3

Subscribe